Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01496534 · ClinicalTrials.gov registry record · Phase 1
Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Matthew Galsky.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT01496534 is a Phase 1 study that was terminated before completion, run by Matthew Galsky. The registered enrollment target is 14 participants.
The verdict
NCT01496534, a Phase 1 study, was terminated before completion, sponsored by Matthew Galsky.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
This is a phase Ib dose escalation study of dovitinib given in combination with either gemcitabine plus cisplatin or carboplatin in patients with advanced solid tumors. Patients with advanced solid tumors, for whom treatment with gemcitabine plus cisplatin or carboplatin would otherwise be warranted, will be enrolled. The dose of dovitinib will be escalated in successive cohorts using standard "3+3" dose escalation rules. Patients will continue treatment, in the absence of prohibitive toxicity, until disease progression. The study will define the recommended phase II dose of these combination regimens.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2012-01 |
| Est. Completion | 2013-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01496534
The ClinicalTrials.gov registry entry for NCT01496534 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carboplatin is the first listed.
NCT01496534 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01496534 about?
NCT01496534 is a clinical study titled "Phase Ib Study of Gemcitabine Plus Cisplatin or Carboplatin Plus Dovitinib in Patients With Advanced Solid Tumors". This is a phase Ib dose escalation study of dovitinib given in combination with either gemcitabine plus cisplatin or carboplatin in patients with advanced solid tumors. Patients with advanced solid tumors, for whom treatment with gemcitabine plus cisplatin or carboplatin would otherwise be warranted...
What is the current status of trial NCT01496534?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2012-01. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01496534?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG).
Who is sponsoring clinical trial NCT01496534?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.